BioSpace News Archive

Osprey Medical, Inc. (ASX:OSP) (Osprey or the Company) is pleased to announce that the Company has received CE Marking for the DyeVert Power XT 2nd generation device.

Avrio Health L.P., a subsidiary of Purdue Pharma L.P. (“Purdue”), is reporting encouraging preliminary results of an in vitro (laboratory) study assessing Betadine® Antiseptic Sore Throat Gargle

Subtle Medical is approved for Phase II of its NIH SBIR grant to develop an innovative artificial intelligence (AI)-powered software, SubtleGAD™, which uses deep learning (DL) to reduce gadolinium dosage needed during MRI exams.

Manhattan Scientifics, Inc. (OTCQB:MHTX) owns 50+ Million shares of its former wholly-owned subsidiary cancer diagnostic company Imagion Biosystems Ltd. (AX:IBX).

Avadim Health, Inc. (“Avadim”), a high-growth, healthcare and wellness company, today announced the acceleration of its strategy to partner with the nation’s largest urology group practices for the management of our nation’s number one infection, urinary tract infections (UTI) and patients suffering from recurrent urinary tract infections (RUTI) by utilizing Theraworx® Protect U-PAK.

SK Medical Management – a full-service property management firm aimed at delivering outstanding management services for healthcare properties throughout the United States – has added two new properties to its portfolio,

PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotechnology” or the “Company”), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology

Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announces financial results for the quarter ended June 30, 2020, and will host an earnings call on August 13, 2020 at 4:30 p.m.

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, provides a corporate update and reports financial results for the three and six months ended June 30, 2020.

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the second quarter ended June 30, 2020 and provided an update on clinical activities.